TSHA
Taysha Gene Therapies (TSHA)
$80
About Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Details
Daily high
$1.83
Daily low
$1.65
Price at open
$1.76
52 Week High
$4.32
52 Week Low
$1.19
Market cap
369.0M
Dividend yield
0.00%
Volume
1.2M
Avg. volume
1.7M
P/E ratio
-4.73
Taysha Gene Therapies News
Details
Daily high
$1.83
Daily low
$1.65
Price at open
$1.76
52 Week High
$4.32
52 Week Low
$1.19
Market cap
369.0M
Dividend yield
0.00%
Volume
1.2M
Avg. volume
1.7M
P/E ratio
-4.73